CN114127109A - 靶向Claudin18.2的抗体或嵌合抗原受体 - Google Patents

靶向Claudin18.2的抗体或嵌合抗原受体 Download PDF

Info

Publication number
CN114127109A
CN114127109A CN202080000840.1A CN202080000840A CN114127109A CN 114127109 A CN114127109 A CN 114127109A CN 202080000840 A CN202080000840 A CN 202080000840A CN 114127109 A CN114127109 A CN 114127109A
Authority
CN
China
Prior art keywords
antibody
antigen
seq
binding fragment
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080000840.1A
Other languages
English (en)
Other versions
CN114127109B (zh
Inventor
宋德勇
周立
董创创
宁振飞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shandong Boan Biotechnology Co Ltd
Original Assignee
Shandong Boan Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shandong Boan Biotechnology Co Ltd filed Critical Shandong Boan Biotechnology Co Ltd
Publication of CN114127109A publication Critical patent/CN114127109A/zh
Application granted granted Critical
Publication of CN114127109B publication Critical patent/CN114127109B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/461Cellular immunotherapy characterised by the cell type used
    • A61K39/4611T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/463Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631Chimeric Antigen Receptors [CAR]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/464Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643Vertebrate antigens
    • A61K39/4644Cancer antigens
    • A61K39/464402Receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/7051T-cell receptor (TcR)-CD3 complex
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70517CD8
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00Animals characterised by species
    • A01K2227/10Mammal
    • A01K2227/105Murine
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • A01K2267/0331Animal model for proliferative diseases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/51Stomach
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72Increased effector function due to an Fc-modification
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/33Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

公开了一种结合Claudin18.2的抗体或其抗原结合片段或嵌合抗原受体,以及其制备方法和用途。所述嵌合抗原受体依次包括本发明的结合Claudin18.2抗原的抗体或其抗原结合片段、胞外铰链区、跨膜区和胞内信号区。本发明所提供的抗体或其抗原结合片段及嵌合抗原受体对分泌Claudin18.2的细胞有更强的亲和力和杀伤能力,以及更好的肿瘤抑制效果。

Description

PCT国内申请,说明书已公开。

Claims (10)

  1. PCT国内申请,权利要求书已公开。
CN202080000840.1A 2019-05-30 2020-05-28 靶向Claudin18.2的抗体或嵌合抗原受体 Active CN114127109B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2019104591291 2019-05-30
CN2019104596223 2019-05-30
CN201910459129 2019-05-30
CN201910459622 2019-05-30
PCT/CN2020/092849 WO2020239005A1 (zh) 2019-05-30 2020-05-28 靶向Claudin18.2的抗体或嵌合抗原受体

Publications (2)

Publication Number Publication Date
CN114127109A true CN114127109A (zh) 2022-03-01
CN114127109B CN114127109B (zh) 2022-06-21

Family

ID=73553501

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080000840.1A Active CN114127109B (zh) 2019-05-30 2020-05-28 靶向Claudin18.2的抗体或嵌合抗原受体

Country Status (9)

Country Link
US (1) US20220204609A1 (zh)
EP (1) EP3929214A4 (zh)
JP (1) JP7266117B2 (zh)
KR (1) KR20220006085A (zh)
CN (1) CN114127109B (zh)
AU (1) AU2020281380B2 (zh)
BR (1) BR112021023897A2 (zh)
CA (1) CA3136281A1 (zh)
WO (1) WO2020239005A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023174405A1 (zh) * 2022-03-18 2023-09-21 广东东阳光药业股份有限公司 Claudin18.2人源化抗体及其应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113645996B (zh) 2019-02-01 2024-04-02 新石生物制药有限公司 抗claudin 18抗体及其使用方法
CN116648261A (zh) * 2020-12-25 2023-08-25 信达生物制药(苏州)有限公司 Claudin18.2嵌合抗原受体以及其用途
CN113416260B (zh) * 2021-04-14 2022-02-01 南京凯地医疗技术有限公司 靶向Claudin18.2的特异性嵌合抗原受体细胞及其制备方法和应用
WO2024118593A1 (en) * 2022-11-28 2024-06-06 Allogene Therapeutics Inc. Claudin 18.2 targeting chimeric antigen receptors and binding agents and uses thereof
CN117777306A (zh) * 2023-07-04 2024-03-29 深圳豪石生物科技有限公司 一种靶向cldn18.2的增强型嵌合抗原受体及其用途

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102139106A (zh) * 2004-05-27 2011-08-03 克鲁塞尔荷兰公司 能中和狂犬病病毒的结合分子及其应用
CN102574923A (zh) * 2009-09-09 2012-07-11 瑞泽恩制药公司 针对人蛋白酶激活受体-2的高亲和力人抗体
WO2016008405A1 (zh) * 2014-07-17 2016-01-21 科济生物医药(上海)有限公司 靶向cld18a2的免疫效应细胞及其制备方法和应用
WO2017041749A1 (zh) * 2015-09-11 2017-03-16 科济生物医药(上海)有限公司 可活化的嵌合受体
WO2018006882A1 (zh) * 2016-07-08 2018-01-11 科济生物医药(上海)有限公司 抗密蛋白18a2的抗体及其应用
WO2018091661A1 (en) * 2016-11-18 2018-05-24 Symphogen A/S Anti-pd-1 antibodies and compositions
CN109206524A (zh) * 2018-09-25 2019-01-15 山东兴瑞生物科技有限公司 抗Claudin18A2嵌合抗原受体、其修饰的T细胞及T细胞制备方法和用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008515774A (ja) * 2004-08-03 2008-05-15 ダイアックス コーポレイション hK1結合タンパク質
WO2013167153A1 (en) * 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
WO2013174404A1 (en) * 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
CN103571872B (zh) 2012-08-09 2016-11-23 山东国际生物科技园发展有限公司 一种能够表达人抗体的转基因动物的制备方法
WO2014075697A1 (en) * 2012-11-13 2014-05-22 Biontech Ag Agents for treatment of claudin expressing cancer diseases
RU2678127C2 (ru) * 2012-11-13 2019-01-23 Бионтех Аг Агенты для лечения экспрессирующих клаудин раковых заболеваний
WO2014127785A1 (en) * 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014146672A1 (en) * 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2016165762A1 (en) * 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Drug conjugates comprising antibodies against claudin 18.2
WO2016180468A1 (en) * 2015-05-11 2016-11-17 Biontech Cell & Gene Therapies Gmbh Claudin-18.2-specific immunoreceptors and t cell epitopes
US11299751B2 (en) * 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
CN109762067B (zh) * 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 结合人Claudin 18.2的抗体及其用途

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102139106A (zh) * 2004-05-27 2011-08-03 克鲁塞尔荷兰公司 能中和狂犬病病毒的结合分子及其应用
CN102574923A (zh) * 2009-09-09 2012-07-11 瑞泽恩制药公司 针对人蛋白酶激活受体-2的高亲和力人抗体
WO2016008405A1 (zh) * 2014-07-17 2016-01-21 科济生物医药(上海)有限公司 靶向cld18a2的免疫效应细胞及其制备方法和应用
WO2017041749A1 (zh) * 2015-09-11 2017-03-16 科济生物医药(上海)有限公司 可活化的嵌合受体
WO2018006882A1 (zh) * 2016-07-08 2018-01-11 科济生物医药(上海)有限公司 抗密蛋白18a2的抗体及其应用
WO2018091661A1 (en) * 2016-11-18 2018-05-24 Symphogen A/S Anti-pd-1 antibodies and compositions
CN109206524A (zh) * 2018-09-25 2019-01-15 山东兴瑞生物科技有限公司 抗Claudin18A2嵌合抗原受体、其修饰的T细胞及T细胞制备方法和用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PRABHSIMRANJOT SINGH等: ""Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer"", 《J HEMATOL ONCOL》 *
左忠林等: ""Claudin-18在胃癌中的临床表达关系与治疗"", 《中华临床医师杂志(电子版)》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023174405A1 (zh) * 2022-03-18 2023-09-21 广东东阳光药业股份有限公司 Claudin18.2人源化抗体及其应用

Also Published As

Publication number Publication date
US20220204609A1 (en) 2022-06-30
CN114127109B (zh) 2022-06-21
EP3929214A4 (en) 2022-06-22
AU2020281380A1 (en) 2021-10-07
CA3136281A1 (en) 2020-12-03
WO2020239005A1 (zh) 2020-12-03
AU2020281380B2 (en) 2024-04-11
EP3929214A1 (en) 2021-12-29
BR112021023897A2 (pt) 2022-01-25
JP7266117B2 (ja) 2023-04-27
JP2022527129A (ja) 2022-05-30
KR20220006085A (ko) 2022-01-14

Similar Documents

Publication Publication Date Title
CN114127109B (zh) 靶向Claudin18.2的抗体或嵌合抗原受体
JP6994456B2 (ja) 抗メソテリン完全ヒト抗体およびメソテリンを標的とする免疫エフェクター細胞
US20220017625A1 (en) Tumor-specific anti-egfr antibody and application thereof
CN108373504B (zh) Cd24特异性抗体和抗cd24-car-t细胞
CN111465616B (zh) 特异性识别恶性b细胞的抗体或其抗原结合片段、包含其的嵌合抗原受体及其用途
WO2022012097A1 (zh) 抗人msln抗体以及靶向msln的免疫效应细胞
WO2023060922A1 (zh) 一种特异性结合cd276的抗体或其抗原结合片段及其制备方法和应用
CN116003628A (zh) 靶向人dll3抗原的全人源特异性嵌合抗原受体及其应用
CN109790533B (zh) 抗pd-l1抗体
CN115698072B (zh) 抗gpc3抗体,抗gpc3嵌合抗原受体和gpc3/cd3双特异性抗体
WO2023072307A1 (zh) 一种靶向cd70的抗原结合片段、单链抗体和嵌合抗原受体及其应用
CN109970859B (zh) Glypican-3特异性抗体及其特异性CAR-T细胞
CN114539410B (zh) Cldn18.2结合抗体、探针及在cldn18.2表达细胞的单细胞测序中的应用
CN116284389A (zh) 抗afp/hla02 tcr样抗体及其用途
CA3136281C (en) Antibody or chimeric antigen receptor which targets claudin 18.2
CN113924316A (zh) 抗cd25抗体及其应用
US20240018262A1 (en) Antibody specific for gpc3 and uses thereof
EP4257608A1 (en) Antibody specific for cd47 and use thereof
WO2024067759A1 (zh) 一种能够结合cldn18.2的抗体或其抗原结合片段及其应用
CN112062848B (zh) 抗cd47单克隆抗体及其应用
WO2022268196A1 (zh) 靶向gpc3的抗原结合蛋白
CN116143948A (zh) 一种以Jurkat为平台的靶向CD24和PD-L1双特异性嵌合抗原受体CAR及其应用
Farhat-Younis et al. Expression of modified FcγRI enables myeloid cells to elicit robust tumor-specific cytotoxicity
CN116063552A (zh) 一种靶向cea的嵌合抗原受体及其应用
CN116640216A (zh) 抗cd19抗体的抗体、抗cd22抗体的抗体及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant